Inclusion Criteria:

- Age between 18 and 70 years

- Patients with histologically confirmed, unresectable, recurrent and/or metastatic
gastric adenocarcinoma

- ECOG performance status ≤1

- Measurable diseases according to the RECIST

- Relapse or refractory after the first-line chemotherapy

- Sign ICF,normal laboratory findings:absolute neutrophil count and platelet count ≥
2.0×109/L and 80×109/L, respectively, hepatic function (total serum bilirubin ≤ UNL,
transaminases ≤ 1.5 times upper normal limit) and renal function (calculated
creatinine clearance ≥ 60 ml/min).

Exclusion Criteria:

- Relapse within 6 months after adjuvant chemotherapy which contained oxaliplatin

- Have used any of drugs in the regimen in first-line chemotherapy

- Pregnant or lactating women,serious uncontrolled diseases and intercurrent
infection

- The evidence of CNS metastasis

- History of other malignancies except cured basal cell carcinoma of skin and
carcinoma in-situ of uterine cervix

- Received other chemotherapy regimen after metastasis

- Participated in other clinical trials.